tirzepatide vs semaglutide efficacy weight loss semaglutide: A new battle in obesity treatment tirzepatide vs semaglutide dosing comparison

Contact us today to schedule a consultation and start your personalized weight loss plan tailored just for you

One-on-one counseling is among the five ways a medical weight loss specialist can help you determine if these injections are right for you

Retatrutide Regulatory Status Retatrutide occupies a unique position because it is not yet FDA-approved: Not FDA-approved currently in Phase 3 clinical trials with Eli Lilly No prescription pathway in the US yet no Mounjaro/Wegovy equivalent for retatrutide Legal as research chemical sold in the US for in-vitro and animal research under research-use-only labeling Likely to receive FDA approval in coming years if clinical trial endpoints meet expectations WADA status currently not specifically listed, though peptide hormones generally fall under WADA categories Not DEA-scheduled no controlled substance status Unlike semaglutide and tirzepatide, retatrutide does not yet exist as a prescription drug

Nausea affected 38-43% of participants

GLP-1 is released from intestinal L-cells in a biphasic pattern following meal ingestion: an initial early peak within 1015 minutes, driven primarily by neural and endocrine signals from the upper gastrointestinal tract, is followed by a sustained second peak at 3060 minutes driven by direct nutrient contact with L-cells in the distal ileum and colon